Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.

• Publication year

  2016

• Venue

  British Journal of Cancer

• Publication date

  2016-02-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.2016.36PMID 26908329PMCID 4800301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

  2015cited by this paper
• New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer

  2015cited by this paper
• Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest

  2015cited by this paper
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

  2014cited by this paper
• Evolution of the cancer stem cell model.

  2014cited by this paper
• Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)

  2014cited by this paper
• New and emerging HDAC inhibitors for cancer treatment.

  2014cited by this paper
• A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.

  2013cited by this paper
• Widespread and Enzyme-independent Nϵ-Acetylation and Nϵ-Succinylation of Proteins in the Chemical Conditions of the Mitochondrial Matrix*♦

  2013cited by this paper
• Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

  2013cited by this paper
• Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis

  2013cited by this paper
• UpSET recruits HDAC complexes and restricts chromatin accessibility and acetylation at promoter regions.

  2012cited by this paper
• Cancer epigenetics: from mechanism to therapy.

  2012cited by this paper
• Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Clinical Toxicities of Histone Deacetylase Inhibitors

  2010cited by this paper
• Histone deacetylases and epigenetic therapies of hematological malignancies.

  2010cited by this paper
• Histone deacetylase inhibitors and genomic instability.

  2009cited by this paper
• Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.

  2009cited by this paper
• The many roles of histone deacetylases in development and physiology: implications for disease and therapy

  2009cited by this paper
• Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.

  2009cited by this paper
• Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

  2008cited by this paper
• The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

  2008cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

  2006cited by this paper
• Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

  2005cited by this paper
• Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

  2005cited by this paper
• Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

  2004cited by this paper
• All trans retinoic acid in acute promyelocytic leukemia

  2001cited by this paper
• All-trans-retinoic acid in acute promyelocytic leukemia.

  1997cited by this paper
• Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

  1988cited by this paper
• Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

  1988cited by this paper

• DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications

  2025cites this paper
• Revisiting epigenetic regulation in cancer: Evolving trends and translational implications.

  2025cites this paper
• LncRNA-Histone Modification Crosstalk: Orchestrating Cancer Pathobiology

  2025cites this paper
• New potent N‐hydroxycinnamamide‐based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP‐1 leukaemia cells

  2025cites this paper
• Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on N-Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer

  2025cites this paper
• Targeting Casein Kinase 2 and Histone Deacetylase with a Dual Inhibitor Effectively Reduces Tumor Growth in a Triple-Negative Breast Cancer Xenograft Model.

  2025cites this paper
• Anticancer properties of histone deacetylase inhibitors – what is their potential?

  2025cites this paper
• HDAC and PI3K dual inhibitors in the treatment of cancers: Current status, trends, and solutions.

  2025cites this paper
• HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism.

  2025cites this paper
• Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics

  2025cites this paper
• RGD-Modified Gold Nanoparticles Loaded with SAHA Remodel the Hypoxic Inflammatory Microenvironment via Inhibiting HIF-1α-VEGF Signaling to Enhance Radiosensitivity in NSCLC

  2025cites this paper
• Histone deacetylases and inhibitors in diabetes mellitus and its complications.

  2024cites this paper
• The Class I Histone Deacetylase Inhibitor as a Potent Therapeutic Target for Treating Glioblastoma and Mocetinostat as a Novel Inhibitor in the Induction Death of Cancer Cells

  2024influential citation
• Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.

  2024cites this paper
• Effect of valproic acid on histone deacetylase expression in oral cancer (Review).

  2024cites this paper
• Hydrazides as Inhibitors of Histone Deacetylases.

  2024cites this paper
• HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation

  2024cites this paper
• Study of TRAIL and SAHA Co-Treatment on Leukemia K562 Cell Line

  2024cites this paper
• Epigenetic Mechanisms Histone Deacetylase–Dependent Regulate the Glioblastoma Angiogenic Matrisome and Disrupt Endothelial Cell Behavior In Vitro

  2024cites this paper
• Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells

  2024cites this paper
• Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia

  2024cites this paper
• Combretastatin A-4 based compounds as potential anticancer agents: A review.

  2024cites this paper
• Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.

  2024cites this paper
• Perspectives on materials: Reality and potential of epigenetic drug nano-delivery

  2024cites this paper
• HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages

  2024cites this paper
• The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods

  2024cites this paper
• Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?

  2023cites this paper
• Mitigative and anti-inflammatory effects of Trichostatin A against radiation-induced gastrointestinal toxicity and gut microbiota alteration in mice

  2023cites this paper
• Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.

  2023cites this paper
• ROLE OF HISTONE DEACETYLASES IN REGULATION OF MACROPHAGE PHAGOCYTOSIS OF MYCOBACTERIUM TUBERCULOSIS

  2023cites this paper
• HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non–small cell lung cancer

  2023cites this paper
• HDACs as an emerging target in endocrine tumors: a comprehensive review

  2023cites this paper
• Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas

  2023cites this paper
• Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.

  2023cites this paper
• Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma

  2023cites this paper
• Potential role of short-chain fatty acids in the pathogenesis and management of acute lymphocytic leukemia

  2023influential citation
• MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells

  2023cites this paper
• The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers

  2023cites this paper
• HDAC inhibitors: Promising agents for leukemia treatment.

  2023cites this paper
• Epigenetic inhibitors and their role in cancer therapy.

  2023cites this paper
• Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

  2023cites this paper
• The role and application of transcriptional repressors in cancer treatment

  2023cites this paper
• Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer

  2022cites this paper
• The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer

  2022cites this paper
• Metabolic control of epigenetic rearrangements in B cell pathophysiology

  2022cites this paper
• A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile

  2022cites this paper
• Molecular targeted therapy: A new avenue in glioblastoma treatment.

  2022cites this paper
• The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting

  2022cites this paper
• Leptin differentially regulate cell apoptosis and cycle by histone acetylation in tibial and vertebral epiphyseal plates

  2022cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• The roles of HDAC with IMPDH and mTOR with JAK as future targets in the treatment of rheumatoid arthritis with combination therapy

  2022cites this paper
• Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis.

  2022cites this paper
• Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study.

  2022cites this paper
• A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation

  2022cites this paper
• Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

  2022cites this paper
• Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

  2022cites this paper
• Single-Cell Transcriptomic Profiling in Inherited Retinal Degeneration Reveals Distinct Metabolic Pathways in Rod and Cone Photoreceptors

  2022cites this paper
• Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma

  2022cites this paper
• Heat Shock Proteins and HSF1 in Cancer

  2022cites this paper
• HDAC Inhibitors: Innovative Strategies for Their Design and Applications

  2022cites this paper
• Mechanical phenotyping reveals unique biomechanical responses in retinoic acid-resistant acute promyelocytic leukemia

  2022cites this paper
• Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.

  2022cites this paper
• Histone deacetylase inhibitor use as a radiosensitizer in solid organ malignancies: a systematic review protocol.

  2022cites this paper
• Effect of Sodium Butyrate on p16INK4a, p14ARF, p15INK4b, Class I HDACs (HDACs 1, 2, 3) Class II HDACs (HDACs 4, 5, 6), Cell Growth Inhibition and Apoptosis Induction in Pancreatic Cancer AsPC-1 and Colon Cancer HCT-116 Cell Lines

  2022cites this paper
• Chromatin Remodeling During Leukemia Cell Proliferation and Differentiation

  2021cites this paper
• Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation

  2021cites this paper
• The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug Oxaliplatin

  2021cites this paper
• When NO . Is not Enough: Chemical Systems, Advances and Challenges in the Development of NO . and HNO Donors for Old and Current Medical Issues

  2021cites this paper
• MMP14 Contributes to HDAC Inhibition-Induced Radiosensitization of Glioblastoma

  2021cites this paper
• An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

  2021cites this paper
• The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies.

  2021cites this paper
• Sh-Sy5y hücre hattında sodyum bütiratın bazı alternatif kırpılma genleri ve BACE1 izoformları üzeindeki etkisi

  2021cites this paper
• Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase.

  2021cites this paper
• Mutual Prodrugs of 5‐Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs

  2021cites this paper
• The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury

  2021cites this paper
• Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8.

  2021cites this paper
• Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.

  2021cites this paper
• Metabolic reprogramming and epigenetic modifications on the path to cancer

  2021cites this paper
• Effects of trichostatin A on FHIT and WWOX genes expression, cell growth inhibition and apoptosis induction in hepatocellular carcinoma WCH 17 cell line

  2021cites this paper
• Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis

  2021cites this paper
• Drug resistance in colorectal cancer: An epigenetic overview.

  2021cites this paper
• Mechanical phenotyping of acute promyelocytic leukemia reveals unique biomechanical responses in retinoic acid-resistant populations

  2021cites this paper
• Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid

  2021cites this paper
• A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials

  2021cites this paper
• Improved development of mouse somatic cell nuclear transfer embryos by chlamydocin analogues, class I and IIa histone deacetylase inhibitors†

  2021cites this paper
• Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction.

  2021cites this paper
• Epigenetic‐based therapy in allogenic hematopoietic stem cell transplantation: Novel opportunities for personalized treatment

  2021cites this paper
• A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo

  2021cites this paper
• Treatment with non-specific HDAC inhibitors administered after disease onset does not delay evolution in a mouse model of progressive multiple sclerosis.

  2021cites this paper
• Epigenetic mechanisms in breast cancer therapy and resistance

  2021cites this paper
• Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models

  2021cites this paper
• Recent advances of dual FGFR inhibitors as a novel therapy for cancer.

  2021cites this paper
• Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing

  2021cites this paper
• A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.

  2021cites this paper
• Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression

  2021cites this paper
• Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.

  2021cites this paper
• Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.

  2021cites this paper
• Cracking a cancer code histone deacetylation in epigenetic: the implication from molecular dynamics simulations on efficacy assessment of histone deacetylase inhibitors

  2020cites this paper
• Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms

  2020cites this paper
• HDAC3 regulates senescence and lineage-specific transcriptional programs in non-small cell lung cancer

  2020cites this paper